Core Viewpoint - The company, KeFu Medical, is planning to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its global strategy and enhance its overseas business capabilities and brand recognition [1][4]. Group 1: Company Overview - KeFu Medical is a comprehensive personal health management enterprise engaged in the research, production, sales, and service of medical devices, covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy [3]. - The company's main brand "KeFu" includes sub-brands such as "JianEr Hearing," "JiRui Medical," "BeiBeiJia," "YanBenShu," and "YangLiDe" [3]. Group 2: Financial Performance - In the first quarter of this year, KeFu Medical reported a revenue of approximately 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of about 91.43 million yuan, down 9.68% year-on-year [6]. - The company's revenue from overseas markets was approximately 5.91 million yuan in 2024, accounting for only 1.98% of total revenue, indicating that its overseas business is still in the cultivation stage [4]. Group 3: Strategic Intentions - The decision to list on the Hong Kong Stock Exchange aligns with national policies supporting companies going global and aims to enhance the company's international development [4]. - The company has completed acquisitions of Shanghai Huazhou and Ximan Na, which are expected to strengthen its overseas business resources [5]. - Future overseas acquisitions will focus on companies that can supplement product lines or enhance technological capabilities, as well as those with established distribution networks or brand influence [5].
赴港上市！背背佳母公司可孚医疗筹划“A+H”，发力海外市场成效几何